Skip to content
    ILMN
    Earnings call· Dec 2024(Q4 FY24)

    ILLUMINA Q4 FY24 earnings call ILMN

    Feb 6, 2025 Source

    Executive summary

    Illumina Q4 FY24 — NovaSeq X Transition Drives Revenue Growth and Margin Expansion

    Illumina delivered Q4 FY24 revenue exceeding expectations, driven by strong NovaSeq X placements and consumable utilization, despite a challenging macroeconomic environment. The company is actively assessing the recent China announcement while reaffirming its commitment to long-term growth and margin expansion through strategic priorities like multiomics expansion and operational excellence.

    Highlights

    5

    • Q4 revenue of $1.1 billion exceeded expectations, growing approximately 1% year-over-year on a constant currency basis.

    • NovaSeq X transition progressing well, with 91 instruments placed in Q4, bringing installed base to 630.

    • Non-GAAP gross margin increased 270 basis points year-over-year to 67.4% due to operational excellence and consumables growth.

    • Achieved over $100 million in cost savings across 2024 from manufacturing and logistics efficiencies.

    • Total sequencing gigabase output on connected high- and mid-throughput instruments grew more than 30% year-over-year.

    Concerns

    3

    • Recent announcement from the Chinese Ministry of Commerce regarding Illumina, with China representing approximately 7% of global revenue.

    • Sequencing instruments revenue declined 3% year-over-year in Q4 due to capital purchase and cash flow constraints impacting customer purchasing behaviors.

    • Mid-throughput shipments declined in Q4 due to customer capital constraints.

    Guidance & targets

    14
    CategoryTargetConfidence
    Full-year 2025 revenue growth
    low single-digit percentage range
    high materiality
    High
    Full-year 2025 non-GAAP operating margin
    approximately 23%
    high materiality
    High
    Full-year 2025 diluted EPS
    $4.50 to $4.65
    high materiality
    High
    Full-year 2025 sequencing consumables growth
    low single digits
    medium materiality
    High
    Full-year 2025 sequencing instrument revenues
    low single-digit decline
    medium materiality
    Medium
    Full-year 2025 non-GAAP tax rate
    approximately 22.5%
    medium materiality
    High
    Q1 2025 revenue
    flat to down 1%
    high materiality
    High
    Q1 2025 non-GAAP operating margin
    approximately 20.5%
    medium materiality
    High
    Q1 2025 non-GAAP EPS
    $0.93 to $0.98
    high materiality
    High
    Long-term revenue growth
    high single-digit percentage growth
    high materiality
    High
    Long-term operating margin expansion
    more than 500 basis points
    high materiality
    High
    Long-term EPS growth
    double-digit to teens
    high materiality
    High
    NovaSeq X transition for high-throughput gigabases
    roughly 75%
    high materiality
    High
    China revenue growth
    approximately flat growth
    medium materiality
    Medium

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Americas
    Revenue growth year-over-year on a constant currency basis, representing more than half of the business.
    		—3%——
    Europe
    Revenue growth year-over-year on a constant currency basis.
    		—3%——
    AMEA
    Revenue decline year-over-year on a constant currency basis.
    		—-10%——
    Greater China
    Revenue growth year-over-year on a constant currency basis, representing approximately 7% of global revenue.
    		—1%——

    Operational metrics

    20
    NovaSeq X pull-through
    $1.3 million
    2024

    Average pull-through per system for the year 2024.

    High-throughput gigabases shipped on NovaSeq X
    over 65%
    Q4 FY24

    Percentage of total high-throughput gigabases shipped that were on NovaSeq X series.

    High-throughput consumables revenue on NovaSeq X
    approximately 40%
    Q4 FY24

    Percentage of total high-throughput consumables revenue from NovaSeq X series.

    Total sequencing Gb output growth
    more than 30%year-over-year
    Q4 FY24

    Growth rate of total sequencing gigabase output on connected high- and mid-throughput instruments.

    Cost savings
    $100 million
    FY24

    Achieved from greater manufacturing and logistics efficiencies across 2024.

    Non-GAAP gross margin
    67.4%increased 270 basis points
    Q4 FY24

    Primarily driven by operational excellence initiatives and consumables growth.

    Non-GAAP operating expenses
    $526 million
    Q4 FY24

    Reflects both cost control measures and project expenditures tied to key investments.

    Non-GAAP operating margin
    19.7%up 120 basis points from last year
    Q4 FY24

    Reflects discipline and operational excellence measures delivering results.

    Non-GAAP tax rate
    23.7%
    Q4 FY24

    Came in lower than expected for the quarter.

    Non-GAAP tax rate
    23.6%
    FY24

    Full year non-GAAP tax rate.

    Non-GAAP net income
    $152 million
    Q4 FY24

    Q4 non-GAAP net income.

    Non-GAAP weighted average diluted share count
    approximately 160 million
    Q4 FY24

    For the fourth quarter.

    Cash flow provided by operations
    $364 million
    Q4 FY24

    Cash generation remains strong.

    Capital expenditures
    $42 million
    Q4 FY24

    Capital expenditures for the quarter.

    Shares repurchased
    134,000 shares
    Q4 FY24

    Repurchased at an average price of $129 per share.

    Amount spent on share repurchase
    $17 million
    Q4 FY24

    Amount spent on repurchasing 134,000 shares at an average price of $129 per share.

    Cash, cash equivalents and short-term investments
    $1.22 billion
    Q4 FY24

    Balance at year-end.

    Clinical volume transitioned to NovaSeq X
    about 50%
    Q4 FY24

    Percentage of clinical volume that has transitioned to NovaSeq X by the end of Q4.

    Research volume transitioned to NovaSeq X
    80%
    Q4 FY24

    Percentage of research volume that has transitioned to NovaSeq X by the end of Q4.

    R&D spend
    just below $1 billion
    per year

    Maintained R&D investment, with focus on effectiveness and efficiency.

    Industry KPIs

    4
    MetricValueDetails
    Revenue EPS guidanceLow single-digit percentage range (revenue); $4.50 to $4.65 (EPS)
    China revenue exposureapproximately 7%%
    Segment organic revenue growthAmericas up 3%; Europe up 3%; AMEA down 10%; Greater China up 1%%
    Instruments vs consumables services mixSequencing consumables revenue $698 million; Sequencing instruments revenue $155 million; Sequencing service and other revenue $151 millionUSD

    Product announcements

    5
    ProductTypeDetails
    single-flow-cell NovaSeq Xlaunch
    new 25B 100- and 200-cycle kits for the NovaSeq Xlaunch
    MiSeq i100launch
    proteomic solutions (in collaboration with Standard BioTools)launch
    constellation mapped REIT technologyexpansion

    Deals & partnerships

    2
    NVIDIACollaboration to bring together Illumina's software capabilities and NVIDIA's advanced AI tools.

    Aims to enable the DRAGEN platform on GPU infrastructure and provide foundational models for biology modeling, driving network effects beyond genomics into multiomics.

    Truveta, Regeneron and several leading health systems across the U.S.Truveta Genome Project to create one of the largest genetic databases linked with phenotypic data.

    Collaboration to build a large genetic database for richer insights, with Illumina technology used for all sequencing.

    Risks & headwinds

    3
    Recent announcement from the Chinese Ministry of Commerce regarding IlluminaCurrent, ongoing

    China represents approximately 7% of our global revenue.

    Mitigation: In dialogue with the relevant parties and promptly seeking additional information to reach a resolution; committed to serving local markets and complying with laws.

    Capital purchase and cash flow constraints impacting customer purchasing behaviorsQ4 FY24, expected to continue in 2025

    Sequencing instruments revenue declined 3% year-over-year in Q4; mid-throughput shipments declined.

    Mitigation: Projecting instrument placements to moderate in 2025; focusing on operational excellence and cost control.

    Macroeconomic and political environmentsFY25

    Assumed continuation of current macroeconomic and political environments in 2025 guidance.

    Mitigation: Closely monitoring evolving circumstances in Washington, particularly as it relates to research funding.

    What to watch in Q1 FY25

    5

    China regulatory resolution

    Next quarter
    CurrentIllumina designated as 'unreliable entity'
    TargetResolution or clarity on impact

    Why it matters

    China represents 7% of global revenue; potential impact on 2025 guidance.

    Our guidance does not attempt to reflect any impact from the recent China announcements, which we are promptly assessing.

    Q&A highlights

    6

    What is the impact of the China announcement on revenue mix and margin profile, and how does it affect the 2025 revenue cadence?

    Management stated the China announcement is very new, they are in dialogue with relevant parties, and China represents ~7% of global revenue. They did not provide further details on China's financial impact. The 2025 revenue growth is expected to be skewed towards the second half of the year due to the NovaSeq X transition.

    “Our guidance does not attempt to reflect any impact from the recent China announcements, which we are promptly assessing.”

    asked by Vijay Kumar · answered by Jacob Thaysen

    2 min read5 chapters

    Detailed Narrative

    01

    China Situation and Outlook

    Illumina is actively engaging with relevant parties regarding the recent announcement from the Chinese Ministry of Commerce, which has designated the company as an "unreliable entity." China represents approximately 7% of global revenue, and the company is committed to serving its customers there while complying with all applicable laws. The 2025 guidance does not reflect any potential impact from this announcement, and the underlying expectation for China revenue in 2025 was approximately flat growth.

    02

    NovaSeq X Transition and Utilization

    The transition to NovaSeq X is progressing well, with 91 instruments placed in Q4, bringing the installed base to 630. NovaSeq X pull-through averaged $1.3 million per system in 2024. By the end of Q4, over 65% of high-throughput gigabases shipped and approximately 40% of high-throughput consumables revenue were on the NovaSeq X series. The company remains on track for roughly 75% of high-throughput gigabases to transition to the X series by the second half of 2025.

    03

    Strategic Priorities and Innovation

    Illumina is focused on three key priorities: deeper customer and partner collaboration, continuous innovation, and commercial/operational excellence. Recent innovations include the launch of the single-flow-cell NovaSeq X, new 25B 100- and 200-cycle kits for NovaSeq X, and the MiSeq i100, which saw over 70 early access placements in Q4. The company is also developing a proteomics solution with Standard BioTools, including a 50,000 UK Biobank sample pilot, and extending its early access program for constellation mapped REIT technology.

    04

    Operational Excellence and Cost Savings

    The company achieved over $100 million in cost savings across 2024 through greater manufacturing and logistics efficiencies. This focus on operational excellence is expected to drive a 170 basis point operating margin improvement in 2025. Further structural cost optimization opportunities are identified for 2025 and 2026, including consolidating manufacturing and R&D capabilities in Singapore and expanding operations in India.

    05

    Multiomics and Ecosystem Expansion

    Illumina is expanding into multiomics through strategic partnerships. A collaboration with NVIDIA aims to enhance multiomics data analysis and interpretation using advanced AI tools, including enabling the DRAGEN platform on GPU infrastructure. The company is also participating in the Truveta Genome Project, alongside Truveta and Regeneron, to sequence 10 million exomes exclusively using Illumina technology, creating one of the largest genetic databases linked with phenotypic data.

    AI-generated summary of the company’s earnings call. Not investment advice.